From GlobeNewswire: 2024-04-04 07:30:00

Trinity Biotech plc announced key business updates, including a comprehensive transformation plan to improve financial performance, targeting $20 million EBITDASO by 2025. The company plans to cease manufacturing at its Kansas City plant, reduce costs, and simplify operations. They also acquired biosensor assets from Waveform Technologies to develop a next-generation continuous glucose monitor. In Q4 2023, total revenues decreased to $13.4 million, with Clinical Laboratory revenues down due to lower haemoglobin, autoimmune, and COVID-19 product sales. Despite challenges, the company remains focused on profitability and growth, with plans for product enhancements and cost savings initiatives.



Read more at GlobeNewswire:: Trinity Biotech Announces Fourth Quarter and Fiscal Year